Reference #: 01060

The University of South Carolina is offering licensing opportunities for this novel method of utilizing systems to target drug resistant bacteria.

Invention Description:

The present invention uses cationic metallocene derivatives to promote the effects of traditional antibiotics against a broad spectrum of bacterial pathogens including drug resistant bacteria. These materials have excellent effects against Gram-negative and Gram-positive bacteria, including various kinds of multidrug-resistant bacteria including Staphylococcus, Enterobacteriaceae, Haemophilus influenzae, Neisseria gonorrhoeae, Klebsiella pneumoniae, Citrobacter, and Morganella.

Advantages and Benefits:

Current antibiotics, especially beta-lactam based drugs, cannot kill most superbugs, such as Methicillin-resistant Staphylococcus aureus (MRSA). This invention provides a new formulation to address this problem. Successful implementation of cationic metallocene-containing compounds and polymers greatly enhance the effects of traditional antibiotics against abroad spectrum of bacterial pathogens, especially drug-resistant bacteria.


Traditional antibiotics, such as penicillins, have been utilized for human health care for decades. However, bacteria are now more and more resistant toward these drugs. Some superbugs show extremely high resistance towards most of the current antibiotics. To overcome such a challenge, one of the most convenient methods is to find new inhibitors to activate traditional antibiotics.

In the past few decades, cationic polymers have been utilized into many applications, such as antimicrobial materials and antifouling coatings. Among them, cationic metallocene-containing polymers are promising candidates for novel medicinal materials due to their unique properties from their metal centers and special frameworks. Though a lot of medical applications from cationic metallocene-containing compounds and polymers exist, only a few of them reported the utilization as antimicrobial materials. None of the work involves the activation of conventional antibiotics to inhibit bacterial pathogens.

Patent Information:
For Information, Contact:
Technology Commercialization
University of South Carolina
Chuanbing Tang
Jiuyang Zhang
Yung-Pin Chen
Alan Decho
© 2019. All Rights Reserved. Powered by Inteum